1Med
7
3
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Efficacy and Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
Role: collaborator
Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage Wrinkles
Role: collaborator
Clinical Investigation on a Polynucleotide-based Device Used to Improve Skin Hydration
Role: collaborator
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
Role: collaborator
POST-MARKETING CLINICAL STUDY to EVALUATE the EFFICACY and SAFETY of the VAGINAL FILLER MEDICAL DEVICE in CORRECTING THINNING of the GENITAL TISSUE of the LABIA MAJORA in WOMEN, RE-PROPORTIONING the FEMALE EXTERNAL GENITAL AREA and IMPROVING SEXUAL FUNCTION.
Role: collaborator
An Interventional Study to Evaluate the Safety and Performance of Crosslinked Hyaluronic Acid Hydrogel
Role: collaborator
L. Casei DG® in Patients With Irritable Bowel Syndrome.
Role: collaborator
All 7 trials loaded